Clinical trials: Bacteremia Due to Staphylococcus Aureus
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Linezolid Plus Standard of Care
The aim of the study is to assess whether targeting virulence factors by administering linezolid in addition to standard antibiotic treatment improves outcomes in patients with Staphylococcus aureus bacteraemia.
- Trial name
- LIPS (NCT06958835)
- Testing
- Linezolid 600 mg
- Where
- 12 sites in Switzerland
- Volunteers
- 606 people
- Sponsor
- University Hospital, Basel, Switzerland
Gram-Positive Bacterial Infections
Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.
- Trial name
- ASSURE (NCT00062647)
- Testing
- Telavancin, Vancomycin, nafcillin, oxacillin, or cloxacillin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Cumberland Pharmaceuticals
MRSA Bacteremia
A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia
The objectives of this study is to exploratory whether Vancomycin + Delpazolid is more effective to the standard of treatment (Vancomycin)/ for hospitalized adults with MRSA bacteraemia.
- Trial name
- NCT05225558
- Testing
- Delpazolid, Vancomycin
- Where
- 6 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- LigaChem Biosciences, Inc.
Staphylococcus Aureus Bacteraemia
Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia
Safety and efficacy of direct thrombin inhibitors versus enoxaparin in patients with staphylococcus aureus bacteraemia. The study hypothesizes that inhibition of the coagulase-activity of S.
- Trial name
- NCT01911624
- Testing
- direct thrombin inhibition, enoxaparin
- Where
- Belgium
- Volunteers
- 94 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Bacterial Endocarditis, Bacteremia
Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus
The purpose of this study is to compare the safety and efficacy of daptomycin, an antibiotic, to standard therapy in subjects who have infective endocarditis or bacteremia due to Staphylococcus aureus (S. aureus).
- Trial name
- NCT00093067
- Testing
- daptomycin
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bacteriemia, Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia
Background Methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia is a common and serious infection, associated with significant morbidity and high mortality rates.
- Trial name
- TriPasCef (NCT07186894)
- Testing
- Antistaphylococcal penicillins, Cefazolin
- Volunteers
- 5,000 people
- Sponsor
- Central Hospital, Nancy, France
Staphylococcus Aureus
Chart Review of Outcome of Treatment for S. Aureus Bacteremia
The purpose of this study is to review medical records at MEDVAMC in order to relate the outcome of bacteremic MRSA infection to the antibiotics selected for treatment.
- Trial name
- NCT00304902
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Methicillin Susceptible Staphylococcus Aureus Septicemia
Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With MSSA Bacteremia
Background: Despite management improvement in lasts years, S.aureus bacteremia leads to high morbidity and mortality. For over 50 years, methicillin-susceptible S.aureus (MSSA) bacteremia standard treatment was cloxacillin.
- Trial name
- SAFO (NCT03959345)
- Testing
- Combination therapy group, Standard therapy group
- Where
- 17 sites in Spain
- Volunteers
- 215 people
- Sponsor
- Miquel Pujol
Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteraemia in Adults
The purpose of this evaluation is to record the management and outcome of adults with S.aureus bacteraemia (SAB) across multiple European, Asian and North American sites and to identify key quality indicators associated with…
- Trial name
- ISAC (NCT02098850)
- Where
- 24 sites in Germany, South Korea and 3 more
- Volunteers
- 2,000 people
- Sponsor
- University of Cologne
Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia
Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia
This is a study of safety and efficacy of ceftaroline fosamil in Subjects with Staphylococcus aureus Bacteremia or with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia persisting after at least 72 hours of…
- Trial name
- NCT01701219
- Testing
- Ceftaroline fosamil
- Where
- 27 sites in United States
- Volunteers
- 56 people
- Sponsor
- Forest Laboratories
Staphylococcus Aureus Infection
Plasma Pharmacological Monitoring of M Penicillins in Methicillin-sensitive Staphylococcus Aureus Bacteremia
The treatment of Methicillin-sensitive Staphylococcus aureus bacteremia is based on the first-line use of cefazolin or M penicillins (oxacillin and cloxacillin).
- Trial name
- DOSESACLOXA (NCT06495697)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteraemia (SAB)-Support-Study
The main objective of this study is to investigate whether checklist-based close telephone consultation and process surveillance for S.
- Trial name
- SABOT (NCT06249451)
- Testing
- Checklist-based phone calls
- Where
- Germany
- Volunteers
- 124 people
- Sponsor
- University Medicine Greifswald
Staphylococcus Aureus, Bacteremia
Echocardiography Versus no Echocardiography in S. Aureus Bacteraemia and VIRSTA Score < 3
Staphylococcus aureus is the most frequent cause of both healthcare-associated and community-acquired bloodstream infections worldwide.
- Conditions
- Staphylococcus Aureus, Bacteremia, Infective Endocarditis
- Trial name
- VIRSTA-VAL (NCT06457386)
- Testing
- systematic echocardiography, no echocardiography arm
- Where
- France
- Volunteers
- 700 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus
Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia
"Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia remains a major cause of community- or hospital-acquired bloodstream infections with an overall mortality estimated around 25%.
- Trial name
- CLOCEBA (NCT03248063)
- Testing
- Cloxacillin, Cefazolin
- Where
- France
- Volunteers
- 315 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Staphylococcus Aureus Infection
Staphylococcus Aureus Bacteremia Antibiotic Treatment Options
Increasing resistance to antibiotic agents has been recognized as a major health problem worldwide that will even aggravate due to the lack of new antimicrobial agents within the next decade [1].
- Trial name
- SABATO (NCT01792804)
- Testing
- Trimethoprim-Sulfamethoxazole, Clindamycin, Linezolid
- Where
- 40 sites in France, Germany and 3 more
- Volunteers
- 215 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Staphylococcus Aureus, Bacteremia
Comparison of Nephrotoxicity and Hospital Costs in Patients With Methicillin-Resistant Staphylococcus Aureus Bacteremia Who Received Vancomycin Versus Teicoplanin Therapy
Staphylococcus aureus, the most virulent of the many staphylococcal species, has been recognized as one of the most important and lethal human bacterial pathogens.
- Trial name
- NCT01352936
- Where
- Taiwan
- Volunteers
- 190 people
- Sponsor
- Taipei Medical University WanFang Hospital
Bacteremia, Endocarditis, Bacterial
Predictors of Infective Endocarditis Among Patients Managed for Staphylococcus Aureus Bacteremia, Particularly Staphylococcus Aureus Bacteriuria, and Time to Blood Culture Positivity
Staphylococcus aureus is a frequent cause of primary or secondary bacteremia. It is also responsible for many cases of infective endocarditis, for which the therapeutic management is specific.
- Trial name
- BACT_URIE (NCT05522764)
- Where
- France
- Volunteers
- 247 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Staphylococcus Aureus Bacteremia
Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia
The Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus aureus Bacteraemia (EVOS) study is a multicentre, randomized, open-label, parallel group, phase 3, non-inferiority trial of early intravenous to oral…
- Trial name
- EVOS (NCT06336824)
- Testing
- Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid, IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
- Where
- 12 sites in Malaysia
- Volunteers
- 290 people
- Sponsor
- Clinical Research Centre, Malaysia
Staphylococcus Aureus Bacteremia
Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia
The primary objective is to determine if early infectious disease (ID) consultation (defined as within 48 hours of a positive blood culture) will reduce mortality rates from Staphylococcus aureus bacteremia (SAB).
- Trial name
- NCT00622882
- Testing
- infectious disease specialist consultation
- Where
- Singapore
- Volunteers
- 200 people
- Sponsor
- National University Hospital, Singapore
Staphylococcus Aureus, Bacteremia
Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia
To study whether fluoroquinolone (trovafloxacin or levofloxacin), added to standard treatment, could reduce the high mortality and complication rates in Staphylococcus aureus bacteremia.
- Conditions
- Staphylococcus Aureus, Bacteremia, Endocarditis, Sepsis
- Trial name
- FINLEVO (NCT00548002)
- Testing
- trovafloxacin and levofloxacin
- Where
- Finland
- Volunteers
- 430 people
- Sponsor
- University of Helsinki